Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
6,486 total articles
Allstate's operational fix for underwriting and catastrophe exposure has produced clear earnings leverage: cheap valuation (P/E ~4.7) and a $56B market cap suggest upside if current trends persist. This is a tactical long trade: the turnaround looks real, but execution and macro/weather risk can still derail the move.
Callaway Golf (ELY) has delivered a clear execution step that should force investors to re-evaluate risk premiums on the name. Management's recent operational wins and product cadence support improving margins and free cash flow over the next few quarters. This trade idea outlines a mid-term long with exact entry, stop and target prices, a catalyst…
Assured Guaranty (AGO) has pulled back to $78.53 after a recent intramonth decline, trading at just under 0.64x book and a sub-9 P/E. Fundamentals and a corporate simplification drive argue for downside protection while technical overshoot and heavy short interest create conditions for a bounce. We lay out an entry at $78.50, a stop at $73.50 and a…
April traffic data shows continued demand resilience for Wizz Air. The low-cost carrier's route mix, fleet efficiency and disciplined capacity expansion support margin recovery. We lay out an actionable trade with entry, stop and target, plus catalysts and key risks that would change the thesis.
Adobe has lost the market's confidence despite a strong business mix, a sizeable $25B buyback and attractive valuation. This trade idea lays out a mid-term (45 trading days) long with exact entry, stop and target, backed by fundamentals, technicals and event catalysts that could force a rerating.
Immunic’s equity looks to have stabilized after a reported $200 million private placement that materially lengthens runway. With a market cap of roughly $158.6M, bullish technicals (RSI ~56, MACD positive) and compressed downside vs. the 52-week high of $15.10, this is a mid-term (45 trading days) trade to capture a recovery toward the prior range.…
Lumentum sits at the center of the AI data center supply chain: lasers, transceivers and photonic components that move massive amounts of data. With a recent run and strategic investments from hyperscaler partners, the business is reporting backlog and capacity tightness that could sustain revenues for years. The valuation is rich, which raises exe…
Fortinet (FTNT) combines high-margin, recurring-security software with strong channel reach and strategic cloud partnerships. Recent wins (Google Cloud Partner of the Year) and robust demand for workload/cloud security underpin a growth-at-a-reasonable-price (GARP) case. Technicals show momentum but also an overbought RSI, so we recommend a discipl…
Heineken (HEINY) looks like a sober, income-oriented long: market cap ~$42.8B, P/E ~20, dividend yield ~2.15% and an active €1.5bn buyback program. Technical momentum is weak, so we recommend a measured long with a $35.50 stop and a $47.63 target over a 180 trading-day horizon.
Vistra (VST) sits at an overlooked intersection: a diversified generation fleet and growing long-term power deals that increasingly include nuclear supply for hyperscale data centers. The market has punished the name on near-term regulatory noise and earnings misses, but the fundamentals and corporate positioning argue for a tactical long trade ove…
Peloton (PTON) is showing early evidence that cost reshape and product refreshes are beginning to stabilize the business. At a $2.24B market cap and a sub-$6 stock price, the asymmetric upside to a return-to-growth scenario is tradeable if risk is tightly managed. I recommend a long trade with a clear entry, stop and target, anchored to improving u…
Kosmos plunged roughly 16% after the 05/05/2026 1Q26 results. That drop creates a controlled-risk long opportunity around $3.00. The company still carries leverage, but recent share issuance raised ~$185M to cut commercial debt, production trends show recovery potential, and the stock trades near a 52-week high of $3.32. We outline an actionable mi…
STRF, Strategy Inc's 10.00% Series A perpetual preferred, trades near $101 and offers an uncommon risk/reward in today's market: durable coupon support plus meaningful upside if market sentiment toward Bitcoin and related products continues to improve. We upgrade to Buy and propose an actionable mid-term trade: entry $100.84, stop $96.00, target $1…
PayPal ($PYPL) trades at an attractive valuation versus its cash generation: roughly $39.6B market cap, $5.5B of free cash flow and a P/E under 8. I added to my position because downside appears limited relative to upside from execution on Venmo, BNPL and checkout products. This is a mid-term swing idea with tight risk management.
Alphabet is trading near $387 after a rapid multi-quarter rebound from last year’s lows. Fundamentals - including $64.4B in free cash flow and a dominant Search franchise - justify holding through an AI-led reacceleration. Technicals show momentum but rising RSI warns of near-term stretch. This trade idea recommends entering at $387.25, a stop at $…
AbbVie is reporting accelerating top-line momentum from its immunology franchise while generating substantial free cash flow and paying a reliable dividend. With Q1 revenue of $15.0B, combined Skyrizi and Rinvoq sales now forecast above $31B in 2026, and $17.8B of free cash flow on the balance sheet, the setup supports a long trade at $207.10 with …
Moody's (MCO) is trading like a cyclical tech name despite a durable, high-margin ratings and analytics franchise. At ~$453, the stock prices in a material slowdown and elevated regulatory risk. We think much of that downside is already reflected in valuations: MCO generates roughly $2.75B in free cash flow, sports an ROE north of 80%, and carries …
Tesla's scale across electric vehicles, Full Self-Driving, robotaxis, energy storage, and AI hardware/software gives it a unique portfolio of optionality. Fundamentals are improving, technicals show bullish momentum, and a conservative trade plan captures upside to near-term highs while limiting downside if macro or regulatory risks flare.
Ouster ($OUST) provides high-resolution digital LiDAR for robotics, vehicles and infrastructure. At $26.67 the stock prices in aggressive growth; this trade targets a mid-term move as adoption and design wins accelerate. Entry $26.67, target $34.00, stop $21.50; horizon: swing (45 trading days).
Vicor is converting a rare combination of fast revenue growth, expanding gross margins and a $301M backlog into cash generation while planning a second fab. The market has priced a lot of upside already, but if management converts backlog into sales and capacity comes online, shares can extend higher. This trade idea lays out an entry at $294.00, a…
Energy Transfer (ET) delivered a blowout Q1 and raised full-year EBITDA guidance, but the market still prices the business at ~8.7x EV/EBITDA with a near-7% yield. For income-oriented growth investors, ET represents an asymmetric setup: operational tailwinds and cash generation support the distribution while valuation can re-rate if midstream funda…
Synopsys' deeper integration of Ansys assets and a string of product launches (notably the Electronics Digital Twin) make its growth story more predictable. The stock trades at a premium, but healthy free cash flow ($2.28B), a raised FY2026 outlook and accelerating IP/security demand create an asymmetric setup. Enter $512.17, stop $480.00, target $…
Intel has repositioned itself as a critical supplier to cloud providers and national AI infrastructure. Market cap sits near $650B while valuation metrics imply the market is pricing in both risk and future growth. This trade targets a measured upside as Intel monetizes custom AI accelerators and foundry wins; set an explicit entry, stop, and targe…
NVIDIA's market value today reflects a dominant GPU/data-center compute business. But the company is also building two other high-margin, high-leverage franchises - enterprise AI software/services and autonomous/edge systems - that the market is only beginning to price. This trade targets a short-duration re-rating as investors reprioritize recurri…
Immuneering (IMRX) has a visible binary catalyst at the end of the month tied to updated clinical data for atebimetinib (IMM-1-104). The market already prices a polarized outcome: strong upside if survival holds and the program continues to de-risk toward Phase 3; sharp downside if data disappoints. With a $336.8M market cap, strong recent institut…
